Cardiovascular Effects of Sunitinib Therapy (CREST)

Overview

Status: Not yet recruiting
Keywords: Renal cell carcinoma , Tyrosine kinase inhibitor , Cardiac toxicity , Hypertension , Ventricular cardiac dysfunction , Sunitinib
IRB Number: 00070591
Specialty: Cardiology, Oncology
Sub Specialties:

Brief Summary

The overall objectives of this study are to further characterize the cardiovascular changes that occur with sunitinib exposure in order to improve our understanding of sunitinib toxicity and determine early, mechanistically and clinically relevant predictors to identify patients at increased risk of hypertension and cardiac dysfunction.  Our specific aims are:

1) To define the changes in arterial hemodynamics that may occur with exposure to sunitinib

2) To define the changes in sensitive echocardiographic measures of cardiac function that may occur with exposure to sunitinib

3) To determine blood markers that are associated with changes in vasculature or cardiac function with exposure to sunitinib.

4) To determine if there are early imaging or biomarker predictors of sunitinib cardiotoxicity.

Principal Investigator: James Fang
Department: Cardiology
Co Investigator: James Fang
Co Investigator: Junfeng Wang
Co Investigator: Neeraj Agarwal
Co Investigator: Jerry Walker

Contact Information

Name:John Kirk
Phone: 801-587-9048
Email: john.kirk@hsc.utah.edu

Inclusion Criteria

1) Patients with renal cell carcinoma starting therapy with sunitinib

2) Age ≥ 18 years

3) ECOG performance status 0, 1, or 2

Exclusion Criteria

1) Any contraindication to sunitinib therapy

2) Life expectancy of less than 3 months

3) Pregnant or previously documented HIV positive

Of note, patients with prior cardiovascular history are not excluded from this study, as long as there are no contraindications to sunitinib therapy.